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Abstract
Objective: The objective of this selective EBM review is to determine whether or not peppermint
oil reduces the symptoms and improves the quality of life in patients with irritable bowel
syndrome (IBS).
Study Design: Review of three randomized, double-blind, placebo controlled clinical trials were
used in this review. The articles were found on PubMed, and selected based on outcomes
measured and relevance to the objective.
Outcomes Measured: The outcomes measured were based on Quality of life and Reduction in
Symptoms. Quality of life was measured using the Persian translation of the SF-6 form for
assessment of quality of life before and after treatment. Reduction of Symptoms was measured
using a mean symptom scores before and after the treatment.
Results: The Merat, et al. study found a statistically significant improvement in reduction of
symptoms including abdominal pain and discomfort, and show a statistically significant
improvement in quality of life. Cappello, et al. also found a statistically significant reduction in
symptoms including abdominal pain, discomfort, bloating, diarrhea and constipation. Alam, et
al. also found a statistically significant reduction in symptoms especially abdominal pain, but did
not see a statistically significant improvement in quality of life.
Conclusions: Based on these three randomized, double-blind, and placebo controlled clinical
trials the efficacy of peppermint oil to treat irritable bowel syndrome is fairly conclusive as an
effective treatment to reduce symptoms. The populations studied in these studies were not large
and lost a lot of patients to follow-up, which are factors that should be addressed in future studies
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Introduction
Irritable Bowel Syndrome (IBS) is a chronic disorder of the GI tract that affects a large
population of people throughout the world. It is a gastrointestinal syndrome characterized by
chronic abdominal pain and altered bowel habits in the absence of any organic cause1. These
symptoms are not explicable by the presence of structural or biochemical abnormalities2. It is
characterized by abdominal discomfort or pain that has two of the following three features:
relieved with defecation, onset associated with a change in frequency of stool, or onset
associated with a change in form (appearance) of stool2. IBS is further categorized into four
different types3. IBS with Constipation (IBS-C) is defined when the person’s stool is hard or
lumpy most of the time, and occasional bowel movements with loose stools3. IBS with diarrhea
(IBS-D) is defined when the person’s stool is loose or watery most of the time and occasional
bowel movements with hard stool3. Mixed IBS (IBS-M) is defined as a mixture of IBS-D and
IBS-C, specifically defined as a person with occasional hard bowel movements and occasional
loose bowel movements3. Unspecified IBS is defined as insufficient abnormality of stool
consistency to meet criteria for the other types of IBS3. There is no single pathophysiological
marker of IBS4.
Despite being a common condition throughout the world, IBS is a chronic troublesome
condition that puts both patients and the healthcare system into heavy expenses as a result of
significant impairment in health-related quality of life and work productivity5. IBS is present in
10% to 20% of adults in the US3. Only about 15% of those affected actually seek medical
attention3. The health care cost of IBS in the US is estimated at $8 billion a year, and IBS is the
most common cause for referral to gastroenterologists, up to 50% of referred patients3.

Farnell, Peppermint Oil and IBS 2
There is no definitive cure for IBS, only therapies to control symptoms. The first-line
treatment for all types of IBS is typically lifestyle and dietary modifications3. The next line of
treatment is pharmacologic treatment to control symptoms. Some examples of pharmacologic
treatment include, laxatives used for constipation predominantly, loperamide for diarrhea not
controlled by diet, and antidiarrheals and antispasmodics are used for diarrhea predominant3.
Other adjunct treatments for IBS include cognitive behavioral therapy or tricyclic
antidepressants3.
Since there is no definitive cure for IBS, various experimental treatments are undergoing
research to become available to control symptoms of IBS. One of those experimental treatments
is peppermint oil. The major component in Peppermint oil, is menthol5. Menthol has relaxing
effects on gastrointestinal smooth muscle by blocking Ca2+ channels in the gut, which may be
useful in improving IBS symptoms5. This systematic review evaluates three randomized control
trials to determine the effectiveness of peppermint oil in reducing symptoms and improving
quality of life for patients with IBS.
Objective
The objective of this selective EBM review is to determine whether or not peppermint oil
reduces the symptoms and improves the quality of life in adult patients with irritable bowel
syndrome (IBS).
Methods
Criteria used for selection of studies for this systematic review is based on population
studied, interventions, and the outcomes measured. The populations studied in these articles
were male and female adults that were diagnosed with IBS using the ROME II criteria. These
patients did not present with any other conditions or had any abnormal lab studies. The
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intervention was a dosage of peppermint oil compared to a visually matched placebo. The
studies measured outcomes using patient-oriented evidence that matters including reduction in
symptoms and improvement in quality of life.
Research for this systematic review was obtained using PubMed to find double-blind,
randomized controlled trials published in peer-reviewed journals within the last 10 years in the
English language. The key words used in searches for these articles were “irritable bowel
syndrome” and “peppermint oil”. The articles selected during this search were based on their
relevance to the objective in this systematic review. This included studies where the participant
groups of adult patients were greater than 18 years old diagnosed with IBS, and whether or not
they evaluated the outcome of the treatment based on patient-oriented evidence that matters. The
exclusion criteria for this systematic review were scientific papers that included patients under
the age of 18 years old, studies that were not randomized, double-blind, placebo controlled trials,
and trials that measured treatment outcomes not based on patient-oriented evidence that matters.
The statistics used by these articles analyzed the data using Chi-square, Mann-Whitney U and
paired and unpaired t-tests. The data from the articles was analyzed in the systematic review
using p-values, Relative Risk Ratio, numbers needed to treat, numbers needed to harm and
Confidence Interval using dichotomous and continuous data from the articles to analyze the
efficacy of peppermint oil in reducing symptoms and improving quality of life in patients with
IBS compared to a visually matched placebo.
Outcomes Measured
The outcomes that were measured in these studies were reduction in symptoms and
quality of life. Merat et. al assessed quality of life in the participants using the Persian
translation of the SF- 36 form for assessment of quality of life5. The SF-36 form was a
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questionnaire that was completed by the researchers when they visited the patients during
treatment follow-up after 1 week and again after 4 weeks. They also used a separate
questionnaire filled out by the researchers to rate the intensity and frequency of each symptom
that was experienced by the patient on a scale of 0-35. The symptoms that were assessed
included abdominal pain, abdominal discomfort, heart burn, nausea, vomiting, abdominal
distention and bloating, increased flatus, decreased or increased passage of stool, stool
consistency, urgency and feeling of incomplete evacuation5. This same questionnaire also
included any adverse events that occurred during the study while taking the treatment. The
patients were also required to fill out a questionnaire that rated 6 different IBS symptoms and
rated a general assessment of health and quality of life on a visual analogue scale (VAS)5. The
patients were asked to complete this questionnaire every night before going to sleep for the first
week, then weekly for the duration of the study5. The patient’s scores on the VAS scale were
converted to a number between 0 and 105. The symptoms that were included on the patient’s
questionnaire were abdominal pain, intestinal gas or bloating, constipation, diarrhea, incomplete
evacuation and urgency.
Cappello et. al assessed reduction of symptoms using symptom score that measured
intensity and frequency of symptoms. Intensity of symptoms were measured on a scale from 0 to
4; with 0 being absent symptoms, 1 being mild, 2 being moderate, 3 being severe and 4 being
unbearable symptoms6. Frequency of symptoms were also measured on a scale of 0 to 4; with 0
being absent, 1 being once per month, 2 being once per week, 3 being twice per week and 4
being more than 3 times per week6. The symptom scores were assessed at the beginning of the
trial, the end of the trial and 4 weeks after the end of the trial6. The symptoms that were
evaluated using the symptom score were abdominal bloating or distention, abdominal pain or
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discomfort, diarrhea (> 3 stool/day), constipation (<3 stools/week), pain at evacuation, urgency
of bowel movement, sense of incomplete evacuation and passage of gas or mucous6. A total IBS
symptom score was then evaluation for each subject, by calculating the mean symptom score for
each symptom, and then adding up the mean symptom scores for all the symptoms for each
patient and getting the average for that6. Any subject with a ≥50% reduction in overall IBS
symptom score from baseline to either at the end of treatment or 4 weeks after treatment was
defined as Remission of IBS symptoms6. Remission of symptoms was how the study defined a
reduction in IBS symptoms for these patients.
Alam et. al assessed the changes in symptoms using a symptom score, which was
assessed before treatment as a baseline, and at 3 week intervals during the treatment and then 2
weeks after the end of treatment4. Quality of life was assessed using a validated IBS quality of
life instrument, which included 34 questionnaires for the patients to fill out4. Quality of life was
assessed before and after treatment4. Three articles were chosen for this systematic review.
Table 1 represents the demographics and characteristics of each study that was selected.
Table 1 - Demographics & Characteristics of included studies
Study
Merat5
(2010)

Type
Randomized
Control Trial

# Pts
60

Age
(yrs.)
36

Inclusion
Criteria
Adult patients
with the
diagnosis of
Irritable bowel
syndrome using
Rome II criteria

Exclusion Criteria
Patients with any
abnormal results, pt.'s
with serum markers
for Celiac Disease, or
other diseases such as
lactose intolerance
and others.

W/D
30

Interventions
Entericcoated
peppermintoil
(Colpermin)
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Cappello6
(2007)

Randomized
double-blind
Control Trial

57

41

Patients
diagnosed with
irritable bowel
syndrome
according to the
Rome II criteria
with no other
abdominal
diseases or
abnormal
diagnostic tests

Patients under 18
years old and over 80
years old; pt.'s with
previous surgery on
abdomen except
appendectomy; pt.'s
with other diseases of
the abdomen

6

Peppermint
oil (Mintoil®)

Alam4
(2013)

Randomized
double-blind
controlled
trial

74

28.74

Patients with
diarrheapredominant IBS
who fulfilled
ROME II criteria

Patient who had red
flag signs such as
weight loss,
dysphagia,
dehydration,
bleeding, recurrent
vomiting, fever, etc.
Pregnant and
breastfeeding women.
Patient who had
concomitant cardiac
disease, liver disease,
renal disease

9

Peppermint
oil

Results
There were three randomized, double-blind, placebo controlled trials selected for this
systematic review to determine the efficacy and safety of peppermint oil for the treatment of
symptoms of IBS in adults. The Merat, et. al study used dichotomous data, but was unable to
base this on an intention-to-treat analysis. The Cappello, et. al study used dichotomous data
based on the intention-to-treat analysis of data. The data presented in Alam et. al, study was
continuous, and couldn’t be converted into dichotomous data4. The analysis of measured
outcomes for each of the studies is based on overall improvement of symptoms, and
improvement in quality of life.
In the Merat et. al study, 90 patients overall were included in this study based on the
inclusion and exclusion criteria, and 60 were able to complete the study with 30 lost to follow-up
(Table 1). This left 33 patients in the peppermint oil group and 27 patients to the placebo group.
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The patients that participated in the study received 187 mg (or 0.2 ml) of peppermint oil
(Colpermin) three times a day 30 minutes before each meal for 8 weeks5. The placebo group
received an identical looking placebo with the same regimen5. The most common presenting
complaints in the beginning of the study was abdominal pain, followed by distention and
flatulence. Quality of life was evaluated during follow-up at 1 week and then again at 4 weeks.
Reduction of symptoms was evaluated every day during the first week and then weekly
throughout the rest of the study. The intensity of the abdominal pain and discomfort was
significantly reduced in the colpermin group at week 8 compared to the placebo (p < 0.001)
(Table 2). Quality of life did not differ significantly at the beginning of the trial. However, after
8 weeks, the patients on Colpermin showed statistically significant improvement in quality of life
according to the SF-6 domains compared to the placebo group (Table 3). Thirty-three patients
reported adverse events including heartburn during the study, 19 in the Colpermin group and 14
in the placebo group.
Table 2: Frequency and Intensity of Symptoms Abdominal pain and Discomfort at 0 and 8
Weeks of Treatment5
Frequency and intensity of Symptoms

Study group

Week 0

Week 4

Week 8

None

PG
CG
PG
CG
PG
CG
PG
CG

0
0
17 (63%)
15 (46%)
9 (33%)
14 (42%)
1 (4%)
4 (12%)

11 (41%)
14 (42%)
10 (37%)
11 (33%)
6 (22%)
7 (21%)
0
1 (3%)

6 (22%)
14 (42%)
7 (26%)
14 (42%)
14 (52%)
5 (15%)
0
0

Occasional
Persistent
Severe

PG= Placebo group, CG= Colpermin (peppermint oil) group

Farnell, Peppermint Oil and IBS 8
Table 3: Mean SF-6 Score in the Beginning and the End of Treatment5
Study group
Placebo Group
Colpermin Group

Mean SF- 6 score beginning of
trial (SD)
48.9 (29.8)
53.7 (26.4)

Mean SF- 6 score end of
trial (SD)
57.8 (29.3)
63.0 (28.2)

p-value
0.308
0.194

Based on the results of the study, the control event rate (CER), which included the
placebo group was 77.7%, whereas the experimental event rate (EER), which included the
peppermint oil group was 57.6%. The Relative Benefit Increase (RBI) was 0.26, and Absolute
Benefit Increase (ABI) was 0.2. Based on these calculations, the numbers needed to treat for this
study was determined to be 5. Meaning that for every 5 people with IBS that are treated with
peppermint oil, 1 more patient will have relief from their symptoms compared to the placebo at 8
weeks.
The calculations for harm were based on the adverse events. The CER for harm was
11%, whereas the EER for harm was 9%. The Relative risk Increase (RRI) for harm was 0.18,
and Absolute risk Increase (ARI) was 0.02. Based on these calculations, the numbers needed to
harm for this study was determined to be 50. Meaning that for every 50 people with IBS who are
treated with peppermint oil, 1 more patient will have an adverse event from treatment compared
to the placebo at 8 weeks.
In the Cappello et. al study, 57 patients met the inclusion and exclusion criteria, 28 were
placed in the peppermint oil group and 29 were placed in the placebo group. Six patients overall
(three from each study group) were lost to follow-up, and were excluded from the study (Table
1). The peppermint oil group was advised to take 1 Mintoil capsule (containing 225mg of
peppermint oil and 45 mg of Natrasorb, which is a starch that absorbs oil in solid powder) twice
a day for 4 weeks6. The placebo group received a capsule that contained 225mg of maltodextrin
with mint flavor and were also advised to take one capsule twice a day for 4 weeks6. At the end
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of 4 weeks of treatment (T4) there was a significantly higher number of patients with a ≥ 50%
reduction in total IBS symptoms score in the peppermint oil group than in the placebo group (p<
0.01). There was also a persisting beneficial effect at another subsequent 4 weeks after that in
the peppermint oil group (p< 0.05), whereas in the placebo group, a significant number of
patients returned to baseline (Table 4).
Table 4: Number of patients with ≥ 50% reduction in total IBS symptom score at end of
treatment (T4) and 4 weeks after end of treatment (T8)6
Study Group

T4

T8

Peppermint oil

64%

46%

Placebo group

34%

10%

Based on the results in the Cappello et. al study, the CER for treatment was 10%,
whereas the EER for treatment was 46%. The RBI for treatment was 3.6, and ABI for treatment
was 0.36. Based on these calculations, the numbers needed to treat for this study was determined
to be 3. Meaning that for every 3 people with IBS who are treated with peppermint oil, 1 more
patient will have relief from their symptoms compared to the placebo at 4 weeks.
In the Alam et. al study, 74 patients were enrolled to participate in the study, and 9
patients dropped out of the study. Thirty-three patients were in the peppermint oil group and
thirty two patients were in the placebo group (Table 1). Before treatment, there was no statistical
difference of mean abdominal pain score between the peppermint oil group and the placebo
group (p< 0.05). At six weeks of treatment, the mean pain score significantly improved in the
peppermint oil group (p>0.001), and was significant over the placebo group (p> 0.05). Two
weeks after the end of treatment, pain score increased in both groups (Table 5). Quality of life
did not improve significantly during this study.
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Table 5: Mean symptom score throughout the study (baseline, 3 weeks, 6 weeks and 2 weeks
after treatment), and mean overall symptom score of both study groups4
Study group

Peppermint oil
Placebo

Baseline

Mean Symptom Score
3 weeks
6 weeks
2 weeks after
treatment

Mean
overall
score

p-value

6.7

6.58

4.94

6.09

4.94

> 0.0001

6.67

6.44

6.15

6.38

6.15

> 0.05

Based on the results in the Alam et. al study, the 95% Confidence Interval (CI) for the
experimental group was 3.75-5.53. The 95% CI for the control group was 5.65-6.65. This
means there is a 95% chance that the groups are different, not by chance. This is significant for
this study showing the results that are significantly different, not by chance, and makes the
results valid. The estimate of treatment affect was fairly precise with p> 0.0001.
Discussion
This systematic review compares three randomized, double blind, placebo controlled
clinical trials, and all of them found that peppermint oil is effective at reducing the symptoms of
IBS4, 5, 6. Merat, et. al found significant improvement of abdominal pain and discomfort, and
found some improvement in quality of life5. Cappello, et. al found significant improvement in
symptoms of IBS in patients after 4 weeks of treatment, and found continued improvement in
symptoms after the treatment6. Alam, et. al specifically found improvement in abdominal pain
and diarrhea symptoms in diarrhea-predominant IBS4.
Peppermint is a plant that belongs to the mint family that is a cross between two types of
mint, water mint and spearmint5, 7. Today, peppermint oil is used as a folk or traditional remedy
for various symptoms including nausea, indigestion, cold symptoms and headaches7. Peppermint
oil appears to be safe for most adults when used in small doses, with possible side effects
including allergic reactions and heartburn7.
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Merat, et. al mentioned a significant limitation to their study was the number of
participants who were lost to follow-up5. Almost 30% of their subjects did not refer for followup, which made them unable to do an intention-to-treat analysis5. Another significant limitation
to their study was the researcher and patient questionnaires were not validated5. They were not
concerned by this because they used the SF-6 questionnaire for analysis, and the results of the
SF-6 questionnaire matched the results of the invalidated researcher and patient questionnaires5.
Cappello, et. al found a significant limitation to their study was the short length of time of the
study, and short follow-up on the patients. They suggested that in future studies therapeutic
periods will be required before the establishment of definite impact of peppermint oil for IBS6.
The limitation in the Alam, et. al study was the sample size and the duration of the treatment4.
They suggested that in future studies, larger placebo controlled trials for a longer period of
treatment are warranted for further evaluation of peppermint oil to reduce symptoms of IBS4.
Conclusion
Based on these three randomized, double-blind, and placebo controlled clinical trials the
efficacy of peppermint oil treatment to reduce symptoms of IBS is fairly conclusive4, 5, 6. The
results for effectiveness in improving quality of life were inconclusive. All three randomized,
double-blind, placebo controlled trials found a statistically significant improvement of symptoms
of IBS, including abdominal pain, bloating and diarrhea, using peppermint oil for treatment4, 5, 6.
In future studies, it would be useful to use larger sample sizes, and conduct the study for
a longer period of time. The larger sample size and longer study observation would show a more
accurate depiction of peppermint oil’s effect on the patient population. This would further
ensure the validity of peppermint oil’s effectiveness at relieving symptoms and improving
quality of life.
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